Joining The Alliance for Regenerative Medicine
CombiGene has been invited to join 240+ other gene and cell therapy and other regenerative medicine-focused organizations to become a part of The Alliance for Regenerative Medicine (ARM).
ARM is based in Washington, D.C. and promotes legislative, regulatory and reimbursement initiatives facilitating advances in gene and cellular therapies and other regenerative medicines worldwide.
CombiGene CEO Bengt Westrin comments: “By joining ARM we will access an international, cutting-edge network within gene therapy, and it will also help us reaching out to business development and investment opportunities in this rapidly evolving field. But not the least, we will also do our very best to contribute to the alliance’s mission and goals”.
For further information:
CombiGene AB (publ)
Bengt Westrin, CEO
Tel: +46 70 265 48 62
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in gene and cellular therapies and other regenerative medicines worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 240 members and is the leading global advocacy organization in this field. To learn more about ARM, please visit www.alliancerm.org.
About CombiGene AB
By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. Current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace AktieTorget. www.combigene.com .
MORE FROM THE COMPANY is a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and PRESS RELEASES are available at www.combigene.com.